SH Pharma (02607) announced interim results: 截至2026年6月30日六個月未經審計中期業績公告, net profit attributable to owners RMB35.0bn Title: 截至2026年6月30日六個月未經審計中期業績公告 Revenue: RMB1474.7bn Net profit: RMB43.4bn Profit attributable to owners: RMB35.0bn
